Novartis ends ALS program after phase 2 flop, adding to R&D woes September 16, 2026Posted inBiotechnology Novartis has extended its losing streak, stopping an amyotrophic lateral sclerosis program after flunking a phase 2 trial. Post navigation Previous Post Why a US senator wants a biotech leader in the White House who ‘has the president’s ear’Next PostRed Light Supercharges Anti-Obesity Drug Precursor
